1887

Abstract

Two experimental feline immunodeficiency virus (FIV) vaccines were tested, either alone or in combination, in four groups of cats (A-D). One vaccine (SL3261-FIV) was composed of live attenuated (SL3261) strains expressing the capsid (Gag) and part of the envelope (Env) proteins of FIV. The other was composed of FIV Gag and Env proteins incorporated into immune- stimulating complexes (iscom-FIV). Cats of group A were immunized four times with SL3261-FIV. Cats of group B were immunized twice with SL3261-FIV and then twice with iscom-FIV. Cats of group C were immunized twice with SL3261 expressing the B subunit of cholera toxin (SL3261-CtxB) and then twice with iscom-FIV. Cats of group D, which served as negative controls, were immunized twice with SL3261-CtxB and then twice with iscom into which the Gag and Env proteins of simian immunodeficiency virus (SIV) had been incorporated (iscom- SIV). Two weeks after the last immunization, all cats were challenged with FIV. At this time, cats immunized with iscom-FIV (groups B and C) showed strong plasma antibody responses to Gag and Env, whilst these responses were weak or undetectable in the cats immunized four times with SL3261-FIV (group A). Seven weeks after FIV challenge, Env-specific antibody responses had increased considerably in cats of all groups except group A. The mean virus loads in the cats of this group proved to be lower than those of the other groups at all time points, indicating partial protection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-12-3265
1997-12-01
2022-08-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/12/9400977.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-12-3265&mimeType=html&fmt=ahah

References

  1. Ackley C. D., Yamamoto J. K., Levy N., Pedersen N. C., Cooper M. D. 1990; Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. Journal of Virology 64:5652–5655
    [Google Scholar]
  2. Aggarwal A., Kumar S., Jaffe R., Hone D., Gross M., Sadoff J. 1990; Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. Journal of Experimental Medicine 172:1083–1090
    [Google Scholar]
  3. Brunner D., Pedersen N. C. 1989; Infection of peritoneal macrophages in vitro and in vivo with feline immunodeficiency virus. Journal of Virology 63:5483–5488
    [Google Scholar]
  4. Charbit A., Martineau P., Ronco J., Leclerc C., Lo-Man R., Michel V., O’Callaghan D., Hofnung M. 1993; Expression andimmunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in an attenuated aroA strain of Salmonella typhimurium upon genetic coupling to two Escherichia coli carrier proteins. Vaccine 11:1221–1228
    [Google Scholar]
  5. Clements J. E., Montelaro R. C., Zink M. C., Amedee A. M., Miller S., Trichel A. M., Jagerski B., Hauer D., Martin L. N., Bohm R. P., Murphey-Corb M. 1995; Cross-protective immune responses induced in rhesus macaques by immunisation with attenuated macrophage-tropic simian immunodeficiency virus. Journal of Virology 69:2737–2744
    [Google Scholar]
  6. Daniel M. D., Kirchhoff F., Czafak S. C., Sehgal P. K., Desrosiers R. C. 1992; Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1941
    [Google Scholar]
  7. De Ronde A., Stam J. G., Boers P., Langedijk H., Meloen R., Hesselink W., Keldermans L. C. E. J. M., Van Vliet A., Verschoor E. J., Horzinek M. C., Egberink H. F. 1994; Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology 198:257–264
    [Google Scholar]
  8. Dittmer U., Nisslein T., Bodemer W., Petry H., Sauermann U., Stahl-Hennig C., Hunsmann G. 1995; Cellular immune responses of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 212:392–397
    [Google Scholar]
  9. Dow S. W., Poss M. L., Hoover E. A. 1990; Feline immunodeficiency virus: a neurotropic lentivirus. AIDS 3:658–668
    [Google Scholar]
  10. Flynn J. L., Weiss W. R., Norris K. A., Seifert H. S., Kumar S., So M. 1990; Generation of a cytotoxic T-lymphocyte response using a Salmonella antigen-delivery system. Molecular Microbiology 4:2111–2118
    [Google Scholar]
  11. Flynn J. N., Keating P., Hosie M. J., Mackett M., Stephens E. B., Beatty J. A., Neil J. C., Jarrett O. 1996; Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. Journal of Immunology 157:3658–3665
    [Google Scholar]
  12. Gonzalez C., Hone D., Noriega F. R., Tacket C. O., Davis J. R., Losonsky G., Nataro J. P., Hoffman S., Malik A., Nardin E., Sztein M. B., Heppner D. G., Fouts T. R., Isibasi A., Levine M. M. 1994; Salmonella typhi vaccine strain CVD908 expressing the circumsporozoite protein of Plasmodium falciparum : strain construction and safety and immunogenicity in humans. Journal of Infectious Diseases 169:927–931
    [Google Scholar]
  13. Hoffmann-Fezer G., Thum J., Ackley C., Herbold M., Mysliwietz J., Thefeld S., Hartmann K., Kraft W. 1992; Decline in CD4 + cell numbers in cats with naturally acquired feline immunodeficiency virus infection. Journal of Virology 66:1484–1488
    [Google Scholar]
  14. Hoiseth S. K., Stocker B. A. D. 1981; Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291:238–239
    [Google Scholar]
  15. Hosie M. J., Osborne R., Reid G., Neil J. C., Jarrett O. 1992; Enhancement after feline immunodeficiency virus vaccination. Veterinary Immunology and Immunopathology 35:191–197
    [Google Scholar]
  16. Hosie M. J., Osborne R., Yamamoto J. K., Neil J. C., Jarrett O. 1995; Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines. Journal of Virology 69:1253–1255
    [Google Scholar]
  17. Hulskotte E. G. J., Geretti A. M., Siebelink K. H. J., Van Amerongen G., Cranage M. P., Rud E. W., Norley S. G., De Vries P., Osterhaus A. D. M. E. 1995; Vaccine-induced virus neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). Journal of Virology 69:6289–6296
    [Google Scholar]
  18. Reid G. 1992; Soluble proteins incorporated into iscoms after covalent attachment of fatty acids. Vaccine 10:597–602
    [Google Scholar]
  19. Rimmelzwaan G. F., Siebelink K. H. J., Huisman R. C., Moss B., Francis M. J., Osterhaus A. D. M. E. 1994; Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. Journal of General Virology 75:2097–2102
    [Google Scholar]
  20. Schödel F., Kelly S. M., Darrell L., Milich D. R., Curtiss R.III 1994; Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination. Infection and Immunity 62:1669–1676
    [Google Scholar]
  21. Siebelink C. H. J., Windrich R. W., Chu I., Groen J., Weijer K., UytdeHaag F. G. C. M., Osterhaus A. D. M. E. 1990; An enzyme-linked immunosorbent assay (ELISA) for the detection of feline immunodeficiency virus (FIV) antigen in cell culture and FIV-specific antibodies in feline serum. Developments in Biological Standardization 72:189–196
    [Google Scholar]
  22. Siebelink K. H. J., Chu I. H., Rimmelzwaan G. F., Weijer K., Osterhaus A. D. M. E., Bosch M. 1992; Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. Journal of Virology 66:1091–1097
    [Google Scholar]
  23. Siebelink K. H. J., Tijhaar E., Huisman R. C., Huisman W., DeRonde A., Darby I. H., Rimmelzwaan G. F., Osterhaus A. D. M. E. 1995; Enhancement of feline immunodeficiency virus infectivity after immunization with envelope glycoprotein subunit vaccines. Journal of Virology 69:3704–3711
    [Google Scholar]
  24. Tijhaar E. J., Yan Z. X., Karlas J. A., Meyer T. F., Stukart M. J., Osterhaus A. D. M. E., Mooi F. R. 1994; Construction and evaluation of an expression vector allowing the stable expression of foreign antigens in a Salmonella typhimurium vaccine strain. Vaccine 12:1004–1011
    [Google Scholar]
  25. Tijhaar E. J., Siebelink K. H. J., Karlas J. A., Burger M. C., Mooi F. R., Osterhaus A. D. M. E. 1997; Induction of feline immunodeficiency virus-specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein. Vaccine 15:587–596
    [Google Scholar]
  26. Tite J. P., Gao X. M., Hughes-Jenkins C. M., Lipscombe M., O’Callaghan D., Dougan G. 1990; Antiviral immunity induced by recombinant nucleoprotein of influenza-A virus. III. Delivery of recombinant nucleoprotein to the immune system using attenuated Salmonella typhimurium as a live carrier. Immunology 70:540–546
    [Google Scholar]
  27. Torten M., Franchini M., Barlough J. E., George J. W., Mozes E., Lutz H., Pedersen N. C. 1991; Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. Journal of Virology 65:2225–2230
    [Google Scholar]
  28. Valentine P. J., Meyer K., Rivera M. M., Lipps C., Pauza D., Maziarz R. T., So M., Heffron F. 1996; Induction of SIV capsid-specific CTL and mucosal sIgA in mice immunized with a recombinant S. typhimurium aroA mutant. Vaccine 14:138–146
    [Google Scholar]
  29. Verschoor E. J., Van Vliet A. L. W., Egberink H. F., Hesselink W., Van Alphen W. E., Joosten I., Boog C. J. P., Horzinek M. C., De Ronde A. 1995; Vaccination against feline immunodeficiency virus using fixed infected cells. Veterinary Immunology and Immunopathology 46:139–149
    [Google Scholar]
  30. Wick M. J., Pfeifer J. D., Findlay K. A., Harding C. V., Normark S. J. 1993; Compartmentalization of defined epitopes expressed in Escherichia coli has only a minor influence on efficiency of phagocytic processing for presentation by class I and class II major histocompatibility complex molecules to T cells. Infection and Immunity 161:4848–4856
    [Google Scholar]
  31. Yamamoto J. K., Okuda T., Ackley C. D., Louie H., Pembroke E., Zochlinski H. A., Munn R. J., Gardner M. B. 1991; Experimental vaccine protection against feline immunodeficiency virus. AIDS Research and Human Retroviruses 7:911–922
    [Google Scholar]
  32. Yamamoto J. K., Hohdatsu T., Olmsted R. A., Pu R., Louie H., Zochlinski H. A., Acevedo V., Johnson H. M., Soulds G. A., Gardner M. B. 1993; Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. Journal of Virology 67:601–605
    [Google Scholar]
  33. Yan Z. X. 1992 Two-phase systemfor the development of live recombinant bacterial vaccines PhD thesis Max Planck Institute, Tübingen, Germany:
    [Google Scholar]
  34. Yan Z. X., Reuss F., Meyer T. F. 1990; Construction of an invertible DNA segment for improved antigen expression by a hybrid Salmonella vaccine strain. Research in Microbiology 141:1003–1004
    [Google Scholar]
  35. Yang D. M., Fairweather N., Button L. L., McMaster W. R., Kahl L. P., Liew F. Y. 1990; Oral Salmonella typhimurium (AroA) vaccine expressing a major Leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against Leishmaniasis. Journal of Immunology 145:2281–2285
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-12-3265
Loading
/content/journal/jgv/10.1099/0022-1317-78-12-3265
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error